Wall Street analyst estimates for Krystal Biotech, Inc. (KRYS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $1.91 | ||
| 2026-08-03 | $1.79 | $1.70 | +5.3% |
| 2026-05-04 | $1.83 | $1.45 | +26.2% |
| 2026-02-17 | $1.70 | $1.62 | +4.9% |
| 2025-11-03 | $2.66 | $1.12 | +137.5% |
| 2025-08-04 | $1.29 | $1.08 | +19.4% |
| 2025-05-06 | $1.20 | $1.38 | -13.0% |
| 2025-02-19 | $1.52 | $1.29 | +17.8% |
Valuation Ratios
| P/E Ratio | 39.88 |
| Price / Book | 7.17 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $1.0M | 0 | 0 | 0 | 0 | $50.7M | $290.5M | $389.1M |
| Cost of Revenue | $2000 | $23000 | $141000 | $974000 | $1.9M | 0 | 0 | $3.1M | $20.1M | $28.8M |
| Gross Profit | -$2000 | -$23000 | $886000 | -$974000 | -$1.9M | 0 | 0 | $47.6M | $270.5M | $360.4M |
| Research & Development | $741000 | $3.2M | $7.8M | $15.6M | $17.9M | $27.9M | $42.5M | $46.4M | $53.6M | $58.0M |
| Selling, General & Admin | $402000 | $1.6M | $4.2M | $6.5M | $13.2M | $40.4M | $77.7M | $98.4M | $113.7M | $146.7M |
| Operating Expenses | $1.1M | $4.8M | $11.9M | $22.1M | $31.1M | $68.3M | $145.2M | $157.3M | $204.8M | $199.1M |
| Operating Income | -$1.1M | -$4.8M | -$11.9M | -$22.1M | -$33.0M | -$68.3M | -$145.2M | -$109.7M | $65.7M | $161.3M |
| EBITDA | -$1.1M | -$4.6M | -$10.7M | -$18.1M | -$30.3M | -$66.2M | -$116.8M | -$91.3M | $109.9M | $196.0M |
| Interest Expense | $7000 | $3.1M | $1.0M | 0 | 0 | $1.5M | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$1.1M | -$7.9M | -$10.9M | -$19.1M | -$32.2M | -$69.6M | -$140.0M | $12.9M | $95.4M | $189.5M |
| Income Tax | 0 | 0 | -$20141 | 0 | 0 | 0 | 0 | $2.0M | $6.2M | -$15.4M |
| Net Income | -$1.1M | -$7.9M | -$10.9M | -$19.1M | -$32.2M | -$69.6M | -$140.0M | $10.9M | $89.2M | $204.8M |
| EPS | $-0.27 | $-1.48 | $-0.97 | $-1.20 | $-1.71 | $-3.13 | $-5.49 | $0.40 | $3.12 | $7.08 |
| EPS (Diluted) | $-0.27 | $-1.48 | $-0.97 | $-1.20 | $-1.71 | $-3.13 | $-5.49 | $0.39 | $3.00 | $6.84 |
| Shares Outstanding (Diluted) | $4.3M | $5.4M | $11.2M | $15.9M | $18.8M | $22.2M | $25.5M | $27.8M | $29.7M | $30.0M |
Price
| Price | $337.99 |
| Market Cap | $10.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACLX · ALKS · ARWR · CRSP · MTSR · PCVX · PTCT
Explore sector: Healthcare · Biotechnology
More sections of KRYS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks